3LIL image
Entry Detail
PDB ID:
3LIL
Title:
Human MMP12 in complex with non-zinc chelating inhibitor
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2010-01-25
Release Date:
2010-09-01
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Free:
0.18
R-Value Work:
0.15
R-Value Observed:
0.15
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Macrophage metalloelastase
Mutations:F171D
Chain IDs:A
Chain Length:159
Number of Molecules:1
Biological Source:Homo sapiens
Peptide-like Molecules
PRD_000803
Primary Citation
Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.
J.Biol.Chem. 285 35900 35909 (2010)
PMID: 20817735 DOI: 10.1074/jbc.M110.139634

Abstact

After the disappointment of clinical trials with early broad spectrum synthetic inhibitors of matrix metalloproteinases (MMPs), the field is now resurging with a new focus on the development of selective inhibitors that fully discriminate between different members of the MMP family with several therapeutic applications in perspective. Here, we report a novel class of highly selective MMP-12 inhibitors, without a phosphinic zinc-binding group, designed to plunge deeper into the S(1)' cavity of the enzyme. The best inhibitor from this series, identified through a systematic chemical exploration, displays nanomolar potency toward MMP-12 and selectivity factors that range between 2 and 4 orders of magnitude toward a large set of MMPs. Comparison of the high resolution x-ray structures of MMP-12 in free state or bound to this new MMP-12 selective inhibitor reveals that this compound fits deeply within the S(1)' specificity cavity, maximizing surface/volume ratios, without perturbing the S(1)' loop conformation. This is in contrast with highly selective MMP-13 inhibitors that were shown to select a particular S(1)' loop conformation. The search for such compounds that fit precisely to preponderant S(1)' loop conformation of a particular MMP may prove to be an alternative effective strategy for developing selective inhibitors of MMPs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures